These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11099901)

  • 1. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.
    Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
    Transfus Sci; 2000 Dec; 23(3):241-2. PubMed ID: 11099901
    [No Abstract]   [Full Text] [Related]  

  • 2. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
    Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
    Blood; 2001 Feb; 97(3):792-8. PubMed ID: 11157499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.
    Breuer W; Ronson A; Slotki IN; Abramov A; Hershko C; Cabantchik ZI
    Blood; 2000 May; 95(9):2975-82. PubMed ID: 10779448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.
    Porter JB; Abeysinghe RD; Marshall L; Hider RC; Singh S
    Blood; 1996 Jul; 88(2):705-13. PubMed ID: 8695819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and therapy of iron overload with desferrioxamine].
    Andres J; Stobbe H
    Z Gesamte Inn Med; 1984 Apr; 39(8):167-9. PubMed ID: 6730593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
    al-Refaie FN; Wickens DG; Wonke B; Kontoghiorghes GJ; Hoffbrand AV
    Br J Haematol; 1992 Oct; 82(2):431-6. PubMed ID: 1419825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desferrioxamine in the management of dialysis hemosiderosis.
    Krumlovsky FA
    Int J Artif Organs; 1982 Jul; 5(4):223-5. PubMed ID: 7118282
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH
    Curr Top Hematol; 1978; 1():127-50. PubMed ID: 400529
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron overload in cardiac valvular disease and pure red cell aplasia: treatment with desferrioxamine.
    Hehlmann R; Schmitz H; Krüger K
    Int J Cardiol; 1984 Jun; 5(6):749-53. PubMed ID: 6235195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferritin-associated iron induces neutrophil dysfunction in hemosiderosis.
    Cantinieaux B; Janssens A; Boelaert JR; Lejeune M; Vermylen C; Kerrels V; Cornu G; Winand J; Fondu P
    J Lab Clin Med; 1999 Apr; 133(4):353-61. PubMed ID: 10218766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts in the overall management of thalassemia.
    Propper RD
    Ann N Y Acad Sci; 1980; 344():375-83. PubMed ID: 6930877
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of iron overload in adults with continuous parenteral desferrioxamine.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Am J Med; 1977 Dec; 63(6):958-66. PubMed ID: 605917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron overload? In sickle cell disease?
    Day S; Dancy R; Kelly K; Wang W
    MCN Am J Matern Child Nurs; 1993; 18(6):330-5. PubMed ID: 8295522
    [No Abstract]   [Full Text] [Related]  

  • 15. Ability to determine the desferrioxamine-chelatable iron fractions of nontransferrin-bound iron using HPLC.
    Koba M; Słomka A; Bączek T; Marszałł MP; Zekanowska E
    J Sep Sci; 2013 Feb; 36(4):665-9. PubMed ID: 23355397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of desferrioxamine B. A new iron eliminating agent, on cases of secondary haemosiderosis in children.
    el-Gholmy A; Khalifa AS; Rahman YA; el-Bagoury I
    J Trop Med Hyg; 1969 Jan; 72(1):22-6. PubMed ID: 5773810
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 19. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
    Srichairatanakool S; Thephinlap C; Phisalaphong C; Porter JB; Fucharoen S
    Med Chem; 2007 Sep; 3(5):469-74. PubMed ID: 17897073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Isoferritin profile of serum ferritin in patient's with secondary hemosiderosis treated with desferrioxamine].
    Mariańska B; Eber M; Oberling F
    Acta Haematol Pol; 1982; 13(3-4):65-72. PubMed ID: 7184299
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.